Short Interest in Oculis Holding AG (NASDAQ:OCS) Grows By 133.7%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 45,100 shares, an increase of 133.7% from the September 30th total of 19,300 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 36,400 shares, the short-interest ratio is presently 1.2 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Oculis in a report on Wednesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Oculis has a consensus rating of "Buy" and a consensus price target of $29.20.

Oculis Trading Down 0.9 %

Shares of NASDAQ OCS traded down $0.15 during trading hours on Friday, hitting $15.80. 49,769 shares of the company traded hands, compared to its average volume of 34,914. The company's 50 day moving average price is $12.97 and its 200 day moving average price is $12.24. Oculis has a 12 month low of $9.05 and a 12 month high of $16.70. The stock has a market capitalization of $639.96 million, a price-to-earnings ratio of -8.88 and a beta of 0.30. The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.13). Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. The firm had revenue of $0.27 million during the quarter, compared to analysts' expectations of $0.28 million. On average, equities research analysts anticipate that Oculis will post -2.19 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.